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ABSTRACT 
Background: In this study, we assess the effectiveness of inhaled doxycycline, a tetracycline antibiotic 
displaying matrix metalloproteinases (MMP) inhibitory effects to prevent allergen-induced inflammation, 
hyperresponsiveness and remodeling. MMPs play key roles in the complex cascade of events leading to 
asthmatic phenotype. 
Methods: Doxycycline was administered by aerosols by the mean of a novel formulation as a complex with 
hydroxypropyl-gamma-cyclodextrin (HP-gamma-CD) used as an excipient. BALB/c mice (n = 16-24 in each 
group) were sensitized and exposed to aerosolized ovalbumin (OVA) from day 21 to 27 (short-term exposure 
protocol) or 5 days/odd weeks from day 22 to 96 (long-term exposure protocol). 
Results: In the short-term exposure model, inhaled doxycycline decreased allergen-induced eosinophilic 
inflammation in bronchoalveolar lavage (BAL) and in peribronchial areas, as well as airway 
hyperresponsiveness. In lung tissue, exposure to doxycycline via inhaled route induced a fourfold increase in IL-
10 levels, a twofold decrease in IL-5, IL-13 levels and diminished MMP-related proteolysis and the proportion 
of activated MMP-9 as compared to placebo. In the long-term exposure model, inhaled doxycycline significantly 
decreased the extent of glandular hyperplasia, airway wall thickening, smooth muscle hyperplasia and 
subepithelial collagen deposition which are well recognized features of airway remodeling.  
Conclusion: Doxycycline administered by aerosols decreases the allergen-induced airway inflammation and 
hyperresponsiveness and inhibits the development of bronchial remodeling in a mouse model of asthma by 
modulation of cytokines production and MMP activity. 
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Abbreviations: BAL, bronchoalveolar lavage; FEV1, forced expiratory volume at the first second; HP-gamma-
CD, hydroxypropylgamma-cyclodextrin; IL, interleukin; LPS, lipopolysaccharide; LTE, long-term exposure 
model; Mch, methacholine; MMP, matrix metalloproteinase; NaCl, sodium chloride; OVA, ovalbumin; PAS, 
periodic acid schiff; Penh, enhanced pause; SDS, sodium dodecyl sulfate; STE, short-term exposure model. 
1. INTRODUCTION 
Asthma is an inflammatory disease of the airways. Assorted inflammatory cells infiltrate bronchial walls and 
bronchial hyperresponsiveness develops. During timelife, some morphological changes occur in the bronchial 
tree referred to as bronchial remodeling. Main changes described in bronchi of asthmatics are: (a) a sub-
epithelial fibrosis mainly made of collagen (type I and III) and fibronectin, (b) some changes of the extracellular 
matrix composition, (c) a smooth muscle cell hyperplasia, (d) a "Goblet cell" hyperplasia, and probably (e) a 
perichondral fibrosis [1]. Despite controller medications available today, symptoms are not totally under control 
in many patients and current therapies are not able to stop the exaggerated decrease of FEV1 (forced expiratory 
volume at the first second) linked to bronchial extracellular matrix remodeling [2]. 
Cytokines (especially Th2), and chemokines play an important role in the installation and persistence of 
inflammation in asthma [3-6]. Mechanisms of airway hyperresponsiveness, inflammation and remodeling can be 
approached using mice models of asthma based on either short-term exposure to allergens (allowing the study of 
hyperreactivity and acute inflammation) [7] or on long-term exposure to allergens (allowing the observation of 
an allergen-induced airway remodeling) [8]. 
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Matrix metalloproteinases (MMPs) are zinc- and calcium-dependent enzymes involved in many inflammatory 
processes including asthma [9]. MMPs are regulators of extracellular matrix turnover and control critical steps of 
smooth muscle and endothelial cell migration and proliferation [10]. Increased levels of MMP-9 have been 
detected in bronchial secretions from asthmatics [11,12], and after allergen challenges [13,14]. MMP-9 gene 
deletion in mice inhibits allergen-induced airway inflammation and hyperresponsiveness in a murine model of 
asthma [7,15]. Similar results have been obtained in mice with chemical compounds displaying a wide spectrum 
of MMP inhibitory effects [16]. To date, none of the MMP-modulating compounds have been used as an inhaled 
therapy and a modulation of allergenrelated bronchial remodeling by MMP inhibitors has never been reported. 
Doxycycline belongs to the family of tetracycline antibiotics and inhibits bacterial protein synthesis. 
Doxycycline is an effective inhibitor of cell proliferation, migration, and MMP activity [17]. Those varied 
biological effects are ascribed to a MMP inhibition [18]. Mechanism(s) of MMP inhibition by doxycycline are 
not yet completely understood to date. Doxycycline could either bind directly Zn2+ or Ca2+, directly target active 
site of MMPs, render pro-enzyme susceptible to fragmentation during activation process [19], induce a 
degradation of the pro-MMP zymogen [20] or provoke an inhibition of the transcription of MMP mRNAs. 
Doxycycline has been proposed as a therapy for many diseases implicating MMP-9, e.g. diseases of the ocular 
surface [21], aortic aneurysms [22], central nervous system disorder [18] and colorectal cancers [23]. It was also 
suggested that some tetracyclines display, in uitro, the ability to decrease IgE responses [24]. When considering 
doxycycline as an antibiotic, the minimal concentration inducing an inhibition of bacteria is generally considered 
to be about 2 mM while the MMP inhibitory effect is present for concentrations 100 times lower. For instance, 
concentrations required to inhibit 50% of the gelatinolytic activity (IC50) were found to be 30-50 µM [25,26]. 
Due to its intrinsic properties of MMP inhibitory agent and considering the role of MMPs in the pathogenesis of 
asthma, we hypothesised that doxycycline could be a disease modifying agent such as demonstrated for anti-
tumor necrosis factor-alpha (TNF-alpha) in rheumatoid arthritis [27] and recently in asthma [28]. 
In this study, we developed a new formulation of doxycycline allowing aerosol administration and we 
demonstrate that a strategy based on MMP inhibition may lead to obtain a control of the allergen-induced airway 
inflammation, hyperresponsiveness and remodeling. We compared results with those obtained with an inhaled 
steroid routinely used for asthma therapy (fluticasone). The development of an aerosolized form of doxycycline 
was performed in accordance with our previously published data, assessing the toxicity of inhaled cyclodextrins 
in mice [29]. 
2. MATERIALS AND METHODS 
2.1. Doxycycline solutions and nebulization 
In the present study, we used doxycycline base USP XXIV (Kunsfan chem. and pharm factory, India) solutions 
buffered at pH 7.4. Unfortunately, in these conditions, doxycycline is not stable and has low solubility. In order 
to enhance doxycycline solubility and stability, inclusion complexes with HP-gamma-cyclodextrin (HP-gamma-
CD) (Wacker, Germany) were investigated. Cyclodextrins are cyclic oligosaccharides consisting of alpha 1-4 
linked glucopyranose units characterized by a lipophilic cavity and a hydrophilic outer surface. Their apolar 
cavity is able to include large organic molecules by non-covalent interaction forces, and thereby to improve their 
water solubility. 
Phase diagram studies showed that HP-gamma-CD is able to improve the doxycycline solubility in buffered (pH 
7.4) solutions. We have previously studied the feasibility of using CDs for the elaboration of pharmaceutical 
formulations designed for inhalation [29]. We described in this reference that depending on the CD 
concentration, the aqueous solutions can undergo aerosolization and that resulting droplet-size is compatible 
with pulmonary deposition. For HP-gamma-CD, the concentration was limited to 50 mM. At this concentration, 
HP-gamma-cyclodextrin allows to solubilize 7.5 mg/ml of doxycycline base. 
Sterile, apyrogenic and isotonic solutions were prepared by dissolving HP-gamma-CD 50 mM and doxycycline 
base (7.5 mg/ml) in a 0.125 M potassium dehydrogenate phosphate buffer (pH 7.4). Cyclodextrins were tested 
following the Bacterial Endotoxin Test described in USP XXVI using Limulus Amebocyte Lysate (LAL). 
Endotoxin levels were <0.15 U/ml. Osmolality of every solution was measured by a Knauer Automatic semi-
micro-Osmometer and adjusted to the value of 300 mOsm/kg by the addition of an adequate amount of NaCl. 
Solutions were stored at -20 °C until nebulization. 
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2.2. Protocol of sensitization and allergen exposure 
Care and use of experimental animals (BALB/c mice) were performed following "principles of laboratory animal 
care" formulated by the National Society for Medical Research (USA) and the experimental protocol was 
approved by the animal ethical committee (University of Liege) under the No. 03/158. Two different protocols 
were used in this study. We first designed a "short term" exposure protocol. In this protocol, 6-8 weeks old 
BALB/c males mice were sensitized on days 1 and 8, by intraperitoneal injection of 10 µg ovalbumin (OVA) 
(Sigma-Aldrich, Schnelldorf, Germany) emulsified in aluminum hydroxide (Alumlnject; Perbio, Erembodegem, 
Belgium). Mice were subsequently divided in five groups: (1) a group of mice was only exposed to the 
inhalation of a PBS aerosol (sham challenge) and four other groups were subjected to ovalbumin (OVA) 1% 
aerosol for 30 min. Before the exposure to OVA, those mice were either exposed during 30 min to (2) PBS 
aerosol, (3) a HP-gamma-CD aerosol (50 mM), (4) a HP-gamma-CD-doxycycline complex (50 mM of HP-
gamma-CD and 7.5 mg/ml of doxycycline), (5) a fluticasone aerosol (1 mg/ml) which was used in this study as 
an anti-inflammatory drug reference therapy. Aerosols were generated daily by ultrasonic nebulizer (Devilbiss 
2000), from day 21 to 27. After determination of airway reactivity, sacrifice of mice was performed on day 28 as 
previously reported [7]. Three different experiments have been performed and measurements have been 
performed on cohorts of 7-14 mice per experimental condition. A "long term" exposure protocol was designed 
and adapted from the short-term exposure protocol. Amendments were made to the short-term exposure protocol 
as follows: mice were sensitized by an intraperitoneal injection on days 1 and 11 and groups of mice were 
exposed to inhalation aerosols 5 days per week (odd week) from day 22 to day 96. No animal died during these 
experiments. 
2.3. Determination of airway reactivity 
Mice were anesthetized by intraperitoneal injection (200 µl) of a mixture of ketamine (10 mg/ml, Merial, 
Brussel, Belgium) and xylazine (1 mg/ml, VMD, Arendonk, Belgium). A tracheotomy was performed by 
insertion of a 20 gauge polyethylene catheter into the trachea. A ligature was performed around the catheter to 
avoid leaks and disconnections. Mice were ventilated with a flexiVent small animal ventilator® (SCIREQ, 
Montreal, Canada) at a frequency of 450 breaths per minute and a tidal volume of 10 ml/kg. A positive 
endexpiratory pressure was set at 2 h Pa. Measurement started after 2 min of mechanical ventilation. A 
sinusoidal 1-Hz oscillation was then applied to the tracheal tube and allowed a calculation of dynamic resistance, 
elastance, and compliance of the airway by multiple linear regressions. A second manoeuvre consisting in an 8-s 
forced oscillatory signal ranging frequencies between 0.5 and 19.6 Hz allowed measurement of impedance to 
evaluate tissue damping, tissue elastance, and tissue hysteresivity [30]. Following measurement of baseline lung 
function, mice were exposed to a saline aerosol (PBS) followed by aerosols containing increasing doses (3, 6, 9, 
12 g/l) of methacholine (ICN Biomedicals, Asse Relegem, Belgium). Aerosols were generated by the mean of an 
ultrasonic nebuliser (SCIREQ, Montreal, Canada) and delivered to the inspiratory line of the flexiVent using a 
bias flow of medical air following the manufacturer's instructions. Each aerosol was delivered for 10 s and 
periods of measurement as described above were made at 1-min intervals following each aerosol. The mean 
airway resistance after methacholine exposure was the main parameter measured during the challenge. 
2.4. Bronchoalveolar lavage (BAL) 
After the sacrifice of mice, a cannula was placed in the trachea of mice and we performed a bronchoalveolar 
lavage by gentle manual aspiration using 4 ml x 1 ml of cold PBS-EDTA 0.05 mM (Calbiochem, Darmstadt, 
Germany) as previously described [7]. The bronchoalveolar fluid (BAL) was centrifuged at 4 °C for 10 min 
(1200 rpm). The supernatant was frozen at -80 °C for protein assessment and the cell pellet was resuspended in 1 
ml PBS-EDTA 0.05 mM. Total cells counts were performed manually, using a thoma chamber. The differential 
cell counts were performed using morphologic criteria on cytocentrifuged preparations (Cytospin) after staining 
with Diff-Quick (Dade, Belgium). Differential cell counts were performed by one blinded observer unaware of 
the experimental treatment. 
2.5. Pulmonary histology 
After BAL, the thorax was opened and the left main bronchus was clamped. The left lung was excised and 
frozen immediately at -80 °C and then crushed in liquid N2 using a Mikro-Dismembrator (Braun Biotech 
International, Gmbh Melsun-gen, Germany). This crushed lung tissue was incubated overnight at 4 °C in a 
solution containing 2 M urea, 1 M NaCl and 50 mM Tris (pH 7.5) and subsequently centrifuged 15 min at 
16.000 x g for protein extraction [7]. The right lung was infused with 4% paraformaldehyde, embedded in 
paraffin and processed for histology. Sections of 5 µm thickness were cut off from paraffin and were stained 
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with haematoxylin-eosin. The extent of peribronchial inflammation was estimated by a score calculated by 
quantification of peribronchial inflammatory cells (eosinophils, lymphocytes, macrophages, etc.), as previously 
described [7]. A value of 0 was adjudged when no inflammation was detectable, a value of 1 when there was 
occasional inflammatory cells, a value of 2 when most bronchi were surrounded by a thin layer (1-5 cells) of 
inflammatory cells and a value of 3 when most bronchi were surrounded by a thick layer (>5 cells) of 
inflammatory cells. Since 5-7 randomly selected tissue sections per mouse were scored, inflammation scores are 
expressed as a mean value and can be compared between groups. Peribronchial inflammation scores were 
assessed by two different observers blinded to the experimental treatment. 
After Congo Red staining, the eosinophilic infiltration in the airway walls was quantified by manual count in 
randomly selected bronchi and normalized to the perimeter of corresponding epithelial basement membrane 
defining an eosinophilic inflammatory score. Glandular hyperplasia was observed using the Periodic Acid Shiff 
(PAS) staining in randomly selected bronchi. PAS stains mucus producing cells (Goblet Cells) and the results 
were expressed as percentages of epithelial cells positive for the PAS staining as counted by an observer blinded 
to experimental data. Masson's Trichrome staining was used to detect peribronchial collagen deposition. We 
developed software in Java 0DK 1.5) that allows one to annotate each image by drawing polygons on top of the 
image (by the means of line-drawing procedure between user-specified successive points and a close operation). 
Each polygon is labeled into a predefined class by the user (here bronchial tubes, vessel, collagen). The user 
saves the annotation, and then the software generates a bitmap image where each pixel within a polygon is 
colored by the color specific to its class. It then counts the number of pixels in the image for each class. The 
percentage of the pixels in the image for a class is returned as the quantification result for that specific class. The 
α-Smooth Muscle Actin (α-SMA) was detected by immunohistochemistry. Slides were treated successively by 
Trypsine 0.1% (Sigma-Aldrich, Schnelldorf, Germany), H2O2 3% (Merck, Darmstadt, Germany), Triton 1% 
(Merck, Darmstadt, Germany) and BSA 10% (Sigma-Aldrich, Schnelldorf, Germany) and then incubated 2 h at 
room temperature with mouse primary antibody anti-α-SMA-FITC (Sigma-Aldrich, Schnelldorf, Germany). 
Slides were washed with PBS and an antibody anti-FITC-POD (Roche, Mannheim, Germany) allows the 
detection of smooth muscle cells layer. 
2.6. Measurement of allergen specific serum IgE 
After sacrifice, blood was drawn from the heart for measurement of OVA specific serum IgE. Ninety-six well 
microtiter plates were coated with 300 µl/well of an OVA solution (5 mg/ 1). Serum was added and, after 
incubation and rinsing, followed by a biotinylated polyclonal sheep anti-mouse IgE (Calbiochem, Darmstadt, 
Germany) used at 1/1000. A serum pool from OVA-sensitized animals was used as internal laboratory standard; 
1U was arbitrarily defined as 1/100 dilution of this pool. 
2.7. Cytokines measurements by ELISA 
In the short-term exposure model, IL-5, IL-10, IL-13, IFN-γ and CCL-11 levels on lung protein extracts were 
assessed using commercial ELISAs (R&D systems, Abingdon, UK). 
2.8. Measurement of MMP activity in lung tissue 
General MMP activity was assessed using the EnzoLyte™520 Generic MMP assay Kit (AnaSpec, San Jose, 
CA). This kit is optimized to detect the activity of different MMPs such as MMP-1, -2, -3, -7, -8, -9, -12, -13 and 
-14, using a fluorescence-quenched substrate (5-FAM/QXL™520). Upon cleavage into two separate fragments 
by MMPs, the fluorescence of 5-FAM is recovered, and can be monitored at excitation/emission wavelengths 
490/520 nm. Proteins extracted from the crushed lung tissue were incubated with 1 mM APMA (4-aminophe-
nylmercuric acetate) during 1 h in order to activate MMPs. 50 µl of sample were incubated in a 96 well plate. 
The plate was incubated at room temperature for 45 min and protected from light. Stop solution from Anaspec 
(50 µl) was added in each well and the fluorescence intensity was measured at 490/ 520 nm. 
2.9. Measurement of MMP-2 and -9 levels by zymography 
Protein extracts were mixed with the same amount of sample buffer. Electrophoresis was carried out on a SDS-
10% polyacrylamide gel containing 1 mg/ml gelatin. Gels were incubated for 30 min in 2% Triton X-100. After 
incubation in an activation buffer containing 100 mM CaCl2 and 100 mM NaCl at 37 °C overnight, gels were 
rinsed and stained for 30 min in Coomassie blue. Gelatinase activity was detected as white lysis bands against 
blue background. Quantitative evaluation of the gelatinolytic activity was performed by scanning gel using an 
imaging densitometer (Bio-Rad Laboratories, Fluor-S™ Multimager, USA). On each gel, we used dilutions of 
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culture medium conditioned by HT1080 cells, known to produce spontaneously high amounts of MMP-2 and -9, 
as an internal standard. Gelatinolytic activity of the murine MMP-2 and -9 was determined by the lysis band in 
the 72 kDa and the 95 kDa area, respectively. 
2.10. Statistical analysis 
All results were expressed as mean ± S.E.M. and the comparison between the groups was performed using non-
parametric Kruskall-Wallis test followed by a Dunn's post-test. Kruskall-Wallis test was performed using 
GRAPHPAD INSTAT version 3.00 for WINDOWS 95 (GRAPHPAD SOFTWARE, San Diego, CA, USA, 
WWW.GRAPHPAD.com). 
3. RESULTS 
3.1. Airway resistance measurement 
Airway resistance was assessed in the short-term exposure model by using the FlexiVent System allowing the 
exposure of mice to inhaled methacholine (3-12 g/l). In the short-term protocol (7 days), allergen exposure did 
induce a bronchial hyperresponsiveness and inhalation of placebo or vehicle (hydroxypropyl-gamma-
cyclodextrin (HP-gamma-CD)) 30 min before allergen did not affect this hyperreactivity to MCh (Fig. 1). On the 
contrary, the exposure to HP-gamma-CD-doxycycline aerosols or fluticasone aerosols 30 min before allergens 
did significantly reduce airway responsiveness to MCh (p < 0.05) (Fig. 1). This decrease of bronchial resistances 
measured in mice exposed to HP-gamma-CD-doxycycline complex or to fluticasone was observed for each dose 
of MCh used. These results clearly suggest that preventive inhalation of HP-gamma-CD-doxycycline complex 
leads to a decrease in bronchial hyperreactivity after allergen exposure. 
 
Fig. 1: Effect of inhaled placebo, excipient, doxycycline, and fluticasone on bronchial reactivity after short-term allergen. Airway 
resistance was measured using FlexiVent System 24 h after the last allergen exposure in mice treated with placebo (n = 5), vehicle only (HP-
gamma-CD) (n = 5), HP-gamma-CD-doxycycline complex (n = 5), and fluticasone (n = 5). ●p < 0.05 compared to HP-gamma-cyclodextrin; 
+p < 0.05 compared to placebo. 
 
 
3.2. Bronchoalveolar lavage (BAL) 
In the short-term exposure model (STE), mice exposed to placebo and subsequently to OVA showed a large 
increase in eosinophil numbers when compared to OVA-sensitized sham-exposed mice (p < 0.005) (Table 1). 
Inhalation of the vehicle (HP-gamma-CD) 30 min before allergen exposure, did not cause any decrease of the 
allergen-induced eosinophil burden while the inhalation of HP-gamma-CD-doxycycline or fluticasone drastically 
reduced the BAL eosinophilia (p < 0.05) (Table 1). Total BAL cell number was also significantly decreased 
when mice were exposed to HP-gamma-CD-doxycycline and fluticasone 30 min before allergen (p < 0.05). 
3.3. Peribronchial inflammation 
A peribronchial inflammation score was evaluated for 5-7 bronchi per mouse. In the short-term exposure model 
(STE), this score was significantly increased by OVA exposure when compared to sham-exposed mice (p < 
0.001) (Fig. 2). The exposure to HP-gamma-CD did not induce any change in peribronchial inflammation. 
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Aerosols of HP-gamma-CD-doxycycline and fluticasone performed before OVA aerosols induced a significant 
decrease of the inflammation score (p < 0.001 and p < 0.005, respectively) (Fig. 2a). 
In the long-term exposure protocol (LTE), baseline inflammation seen in sham-exposed mice was slightly higher 
than in the short-term exposure model. OVA exposure increased peribronchial inflammation (p < 0.001) which 
was notmodified by HP-gamma-CD aerosols while HP-gamma-CD-doxycycline and fluticasone significantly 
prevented the peribronchial inflammation (p < 0.001 and p < 0.005, respectively) (Fig. 2b). Representative 
examples of lung peribronchial inflammation after ovalbumin exposure (left panel) and HP-gamma-CD-
doxycycline inhalation (right panel) are presented in Fig. 2c. 
Eosinophil counts/mm of basement membrane were significantly reducedby HP-gamma-CD-doxycycline or 
fluticasone inhalation 30 min before allergen (p < 0.05) (Fig. 3a). In the long-term exposure protocol, the 
increase in eosinophil counts induced by OVA was smaller but similar results were obtained when considering 
different experimental groups (Fig. 3b). 
 
Table 1: BAL total and differential cell counts (x104/ml) in the short-term exposure protocol 
Cell types PBS (n = 8) 
Placebo 
(n = 25) 
HP-gamma-CD 
(n = 22) 
HP-gamma-CD 
doxycycline (n = 24) 
Fluticasone
(n = 17) 
Epithelial cells 6.5 ± 1.5 4.7 ± 0.5 2.8 ± 0.4a 4.3 ±0.7 4 ± 0.5 
Eosinophils 0.3 ± 0.2b 22.5 ± 3.8 25.4 ± 4.2 7.7 ± 1.2a,c 7.8 ± 1a,c 
Neutrophils 1.1 ±0.3 1 ± 0.2 1.9 ± 0.5 0.3 ± 0.09a,c 0.6 ± 0.3 
Lymphocytes 1 ± 0.5 0.8 ± 0.3 0.6 ± 0.2 0.3 ± 0.08 0.2 ± 0.05 
Macrophages 30.9 ± 6.6 28.4 ± 2.6 22.9 ± 2.5 25.6 ±2.7 26.2 ± 2.2 
Total cells 45.5 ± 13.2 56.8 ± 6 51.4 ±6.1 38.3 ± 3.8a 39.7 ± 2.3a 
a p < 0.05 compared with ovalbumin. 
b Not increased in PBS group as compared to all groups (p < 0.005). 
c p < 0.05 compared with HP-gamma-CD. 
 
3.4. Effects of doxycycline on allergen-induced glandular hyperplasia 
Long-term exposure to allergen did induce a significant increase in the percentage of cells positive for PAS 
staining among epithelial cells. These PAS-positive cells had morphological features of Goblet cells (Fig. 4a). 
HP-gamma-CD aerosols did not modify that percentage significantly HP-gamma-CD-doxycycline or fluticasone 
inhaled before allergen did significantly reduce Goblet cell hyperplasia (p < 0.05 and p < 0.01, respectively) 
without any significant difference between these two groups (Fig. 4b). 
3.5. Effects of doxycycline on allergen-induced epithelium basement membrane thickening 
In the long-term exposure model, exposure of mice to allergen induced a significant increase of the average 
thickness of this membrane (p < 0.001) (Fig. 4c). HP-gamma-CD-doxycycline and fluticasone induced a 
significant inhibition of the allergen-induced basement membrane thickening (p < 0.05 and p < 0.001, 
respectively) (Fig. 4c). 
3.6. Effects of doxycycline on airway wall collagen deposition 
In the long-term exposure group, quantification of collagen deposition in bronchial walls was performed using 
the Java software and allowed us to demonstrate a significant increase of airway wall collagen deposition after 
OVA exposure as compared to sham-exposed mice (p < 0.001). Moreover, this increase in the surface occupied 
by collagen in bronchial walls was not influenced by inhalation of vehicle (HP-gamma-CD). On the contrary, 
HP-gamma-CD-doxycycline and fluticasone did prevent significantly this collagen deposition when compared 
either to placebo (PBS) or vehicle (HP-gamma-CD) (p < 0.001) (Fig. 4d and e). 
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Fig. 2 : Peribronchial inflammation scores in the short-term allergen exposure model (STE) (a) and in the long-term allergen exposure 
model (LTE) (b). Peribronchial inflammation scores were calculated as described in Section 2. Results are expressed as mean and error bars 
represent the S.E.M. Numbers of mice per group: no therapeutic intervention and sham-exposed mice, n = 8 (row 1); placebo-exposed (PBS), 
n = 25 (row 2); HP-gamma-cyclodextrin (CD), n = 22 (row 3); HP-gamma-cyclodextrin-doxycycline pO), n = 24 (row 4); fluticasone (FL),  
n = 17 (row 5). PBS, CD, DO, and FL groups were exposed to allergens (OVA). ***p < 0.001 compared to sham-exposed mice; ●●●p < 0.001 
compared to HP-gamma-cyclodextrin; +++p < 0.005 compared to placebo, (c) Microphotographs (haematoxylin-eosin, 200X) of 
formaldehyde-fixed paraffin-embedded lung sections from mice exposed to ovalbumin and placebo (left panel) or to ovalbumin and HP-
gamma-cyclodextrin-doxycycline complex (right panel) in the short-term exposure model. 
 
 
Fig. 3: Measurements of eosinophilic infiltration in the bronchial tissue in short-term (a) and long-term (b) allergen exposure model. The 
bar graph represents the mean of three independent experiments and errors bars represent S.E.M. Numbers of mice per group: no therapeutic 
intervention and sham-exposed mice, n = 8 (row 1); placebo-exposed (PBS), n = 25 (row 2); HP-gamma-cyclodextrin (CD), n = 22 (row 3); 
HP-gamma-cyclodextrin-doxycycline (DO), n = 24 (row 4); fluticasone (FL), n = 17 (row 5). PBS, CD, DO, and FL groups were exposed to 
allergens (OVA). ***p < 0.001 compared to sham-exposed mice; *p < 0.05 compared to HP-gamma-cyclodextrin; +p < 0.05 compared to 
OVA-exposed mice. 
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Fig. 4: Determination of glandular hyperplasia by PAS staining in the long-term exposure model: (a) microphotographs of representative 
bronchial sections. Left panel: ovalbumin-exposed mice treated with excipient only (HP-gamma-CD) (400X). Right panel: ovalbumin-
exposed mice treated with HP-gamma-CD-doxycycline (400X). (b) Quantitative assessment of mucus producing cells detected by PAS 
staining. Results are expressed as mean percentages of mucus cells in the epithelium. Error bars represent the S.E.M. Numbers of mice per 
group: no therapeutic intervention and sham-exposed mice, n = 8 (row 1); placebo-exposed (PBS), n = 25 (row 2); HP-gamma-cyclodextrin 
(CD), n = 22 (row 3); HP-gamma-cyclodextrin-doxycycline (DO), n = 24 (row 4); fluticasone (FL), n = 17 (row 5). PBS, CD, DO, and FL 
groups were exposed to allergens (OVA). *** p < 0.001 compared to sham-exposed mice; ● p = 0.05 compared to HP-gamma-cyclodextrin; 
++ p = 0.01 compared to OVA-exposed mice, (c) Measurement of thickness of basement membrane in the long-term exposure model: effects 
of inhaled placebo, excipient, doxycycline, and fluticasone on allergen-induced thickening. The basement membrane was measured using 
ImageJ program (see Section 2). The bar graphs represent the mean and error bars correspond to S.E.M. Numbers of mice per group: no 
therapeutic intervention and sham-exposed mice, n = 8 (row 1); placebo-exposed (PBS), n = 25 (row 2); HP-gamma-cyclodextrin (CD),         
n = 22 (row 3); HP-gamma-cyclodextrin-doxycycline (DO), n = 24 (row 4); fluticasone (FL), n = 17 (row 5). PBS, CD, DO, and FL groups 
were exposed to allergens (OVA). *** p < 0.001 compared to sham-exposed mice; ● p < 0.05 compared to HP-gamma-cyclodextrin-
doxycycline complex; +++ p < 0.001 compared to OVA-exposed mice, (d) Microphotographs of lung sections (200X) stained with Masson's 
Trichrome in placebo-exposed mice (left panel) and HP-gamma-cyclodextrin-doxycycline complex (right panel), (e) Quantification of 
collagen deposition in the airways in long-term exposure model: effects of inhaled placebo, excipient, doxycycline, and fluticasone on 
allergen-induced collagen deposition. Results are expressed as mean ± S.E.M. Numbers of mice per group: no therapeutic intervention and 
sham-exposed mice, n = 8 (row 1); placebo-exposed (PBS), n = 25 (row 2); HP-gamma-cyclodextrin (CD), n = 22 (row 3); HP-gamma-
cyclodextrin-doxycycline pO), n = 24 (row 4); fluticasone (FL), n = 17 (row 5). PBS, CD, DO, and FL groups were exposed to allergens 
(OVA). *** p < 0.001 compared to sham-exposed mice; ●●● p < 0.001 compared to HP-gamma-cyclodextrin; +++p < 0.001 compared to 
OVA-exposed mice, (f) Measurements by using immunohistochemistry of the thickness of smooth muscle layer around the bronchi: effects 
of inhaled placebo, excipient, doxycycline, and fluticasone on allergen-induced thickening. Results are expressed as mean ± S.E.M. Numbers 
of mice per group: no therapeutic intervention and sham-exposed mice, n = 8 (row 1); placebo-exposed (PBS), n = 25 (row 2); HP-gamma-
cyclodextrin (CD), n = 22 (row 3); HP-gamma-cyclodextrin-doxycycline (DO), n = 24 (row 4); fluticasone (FL), n = 17 (row 5). PBS, CD, 
DO, and FL groups were exposed to allergens (OVA). *** p < 0.001 compared to sham-exposed mice; ●●● p < 0.001 compared to HP-
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Fig. 4: (Continued). 
 
 
Fig. 5: Levels of mediators in lung protein extracts after allergen exposure. ELISA measurement of IL-13 (a), IL-5 (b) and IL-10 (c) levels 
in the short-term allergen exposure model. Results are expressed as mean ± S.E.M. Numbers of mice per group: placebo-exposed (PBS),          
n = 25 (row 1); HP-gamma-cyclodextrin (CD), n = 22 (row 2); HP-gamma-cyclodextrin-doxycycline (DO), n = 24 (row 3); fluticasone (FL), 
n = 17 (row 4). PBS, CD, DO, and FL groups were exposed to allergens (OVA). ●p < 0.05 compared to HP-gamma-cyclodextrin; +p < 0.05 
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3.7. Effects of doxycycline on smooth muscle thickness 
Long-term allergen exposure induced an increase of smooth muscle layer thickness, measured by 
immunohistochemistry, around the bronchi when compared to sham-exposed mice (p < 0.001). As observed for 
other features of bronchial remodeling, HP-gamma-CD-doxycycline and fluticasone did prevent significantly 
this increase of smooth muscle cells thickness when compared either to placebo (PBS) or vehicle (HP-gamma-
CD) (p < 0.001) (Fig. 4f). 
 
Fig. 6: Measurements of MMP activity and MMP-2 and -9 levels in lung protein extracts. Quantification of general MMP activity in the 
short-term exposure protocol (a) and in the long-term exposure protocol (b). Data are a mean of value measured for 10 mice per group and 
are expressed in µg/ml. Representative examples of zymograms performed on lung protein extracts in the short-term exposure protocol (c). 
Quantification of MMP-9/pro-MMP-9 ratio in the long-term exposure protocol (d). Numbers of mice per group: no therapeutic intervention 
and sham-exposed mice, n = 8 (row 1); placebo-exposed (PBS), n = 25 (row 2); HP-gamma-cyclodextrin (CD), n = 22 (row 3); HP-gamma-
cyclodextrin-doxycycline (DO), n = 24 (row 4); fluticasone (FL), n = 17 (row 5). PBS, CD, DO, and FL groups were exposed to allergens 
(OVA). *p < 0.05 compared to sham-exposed mice; ●p < 0.05 compared to HP-gamma-cyclodextrin; +p < 0.05 compared to OVA-exposed 
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3.8. Measurements of allergen-specific IgE in serum and cytokine levels in bronchoalυeolar lavage and 
lung protein extracts 
OVA-specific IgE levels were increased in serum after allergen exposure (p < 0.05) and there were no difference 
between the experimental groups exposed to allergen inhalation (data not shown). In the short-term exposure 
protocol, we measured levels of CCL-11 (eotaxin), IL-4, IL-5, IL-10, IFN-gamma and IL-13 in lung protein 
extracts. IFN-gamma was not detectable in almost all our samples. CCL-11 levels did not show any significant 
difference (data not shown). IL-13 and IL-5 were both increased in the lung protein extracts of mice exposed to 
allergen and placebo or vehicle. Such an increase was inhibited by a previous exposure to HP-gamma-CD-
doxycy-cline or fluticasone (p = 0.05 and p < 0.05 for IL-13 and IL-5, respectively) (Fig. 5a and b). Most 
importantly, we found an increase of IL-10 levels in lung protein extracts after the inhalation of HP-gamma-CD-
doxycycline when compared to mice exposed to placebo (PBS) or to HP-gamma-CD (p < 0.05). In sharp 
contrast, IL-10 levels were not modified in the group treated by fluticasone (Fig. 5c). 
3.9. MMP activity and MMP-2 and -9 levels in lung proteins extracts 
Global MMP activity was assessed in crushed lung tissue by using a fluorescent substrate in the short-term 
allergen exposure group. MMP-derived enzymatic activity was significantly increased after allergen exposure as 
compared to sham-challenged mice. Exposure to inhaled doxycycline or fluticasone significantly reduced global 
MMP activity when compared to mice exposed to placebo or to vehicle alone (p < 0.05) (Fig. 6a). Similar results 
were found in the long-term exposure model. Mice exposed to OVA aerosols displayed higher MMP activity 
than sham-exposed mice. Doxycycline or fluticasone inhalation performed before each allergen exposure 
decreased global MMP activity as compared to mice exposed to placebo inhalation (p < 0.05) (Fig. 6b). 
MMP-9 and -2 levels, in pro- and activated forms, were detected by zymography in the two protocols. 
Representative example of zymograms obtained in the long-term exposure protocol is shown in Fig. 6c. In long-
term exposure model, levels of MMP-9 and the MMP-9/pro-MMP-9 ratio were drastically reduced after the 
treatment by HP-gamma-CD-doxycycline or fluticasone when compared to OVA-challenged placebo-exposed 
mice (p = 0.005 and p < 0.01, respectively) (Fig. 6d). This huge decrease was also found for pro-MMP-2 levels 
(p = 0.001 and p = 0.005, respectively). 
4. DISCUSSION 
We demonstrate for the first time in the current study that inhaled doxycycline, in an adequate formulation with 
HP-gamma-CD, inhibits the allergen-induced airway reactivity, eosinophilic infiltration in BAL compartment 
and in bronchial walls, and peribronchial inflammation. Furthermore, we provide evidence for the first time that 
inhaled doxycycline prevents allergen-induced bronchial morphological changes and thus inhibits glandular 
hyperplasia, airway wall and smooth muscle layer thickening and peribronchial collagen deposition. Effects of 
doxycycline on tissue remodeling were comparable to those obtained after exposure to fluticasone, an inhaled 
steroid on the market used in the current study as a reference therapy. Mechanisms of pharmacological activity 
of doxycycline in the context of bronchial inflammation were investigated and the main findings are a 
doxycycline-induced MMP inhibition and impairment of Th2 inflammation. Indeed, doxycycline exposure leads 
to a significant increase in the anti-inflammatory cytokine IL-10 and a decrease of IL-5 and IL-13 levels in the 
lung parenchyma. Doxycycline also reduced MMP-9 activation in the lungs from mice exposed to allergens. In 
line with our previous works demonstrating that MMPs and more specifically MMP-9 play a critical role in 
allergen-induced airway inflammation [7,12,13,15,31], we designed the present work as an attempt to control 
airway inflammation and remodeling by a molecule known to be a potent MMP inhibitor. Doxycycline was 
selected because its MMP inhibitory activity was confirmed by numerous studies and because this molecule was 
shown to have a very low toxicity in human adults. To our knowledge, this is the first demonstration that an 
inhaled non-steroidal drug (doxycycline) exerts an effect on both airway inflammation and airway remodeling 
features such as Goblet cells hyperplasia, collagen deposition and basement membrane and smooth muscle cells 
layer thickness. Other researchers have published an interesting report on the inhibition of toluene diisocyanate-
induced airway inflammation by doxycycline [32]. In that paper, however, the drug was given orally at high 
dosages, higher than those currently recommended for antimicrobial therapy and remodeling parameters were 
not assessed. In the present study, mice were challenged with the allergen by an exposure to a new formulation 
given by aerosols and not by intratracheal instillation. Our model may therefore mimic more closely the clinical 
situation by the use of a well-characterized model of allergen-induced inflammation and airway remodeling in 
mice. By using a topical therapeutical approach allowed by an original galenic formulation, our study clearly 
shows that an inhaled doxycycline-based therapy for asthma is of potential interest and is worth to be confirmed 
in other animal models and possibly in humans. 
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Doxycycline in solution without excipient has a very low pH and accidental tetracycline inhalation has been 
reported to be responsible for toxic pneumonia [33]. In addition, doxycycline is only poorly soluble at pH 7.4 
and is not stable with a tendency to precipitate rapidly. We therefore used cyclodextrins (HP-gamma-CD) for 
increasing the solubility and stability of doxycycline at physiological pH. We did previously describe that 
inhaled HP-gamma-CD was non-toxic and did not provoke by itself some modifications of the airway 
architecture or induce inflammation [29]. The selection of this specific cyclodextrin is based on its higher 
potency to increase doxycycline solubility as compared to different related compounds (data not shown), and 
mainly on its safety profile [29]. In the present study, we demonstrate that HP-gamma-CD does not interfere 
with the inflammatory response and does not bear per se any pharmacological activity when used in a topical 
lung application in an inflammatory airway disease. Furthermore, we demonstrated previously that HP-gamma-
CD does not modify the aerosol characteristics in terms of droplet size and nebulization speed in our 
experimental conditions [29]. 
To date, there are still controversies about the exact mechanism for MMP inhibition by tetracyclines. In the 
present study, we investigated whether the topical exposure by inhalation to doxycycline modulated the 
expression of key Th2 and anti-inflammatory cytokines and we found IL-5 and IL-13 production being decreased 
and, interestingly, a large increase in the anti-inflammatory cytokine IL-10 production. To our knowledge, this is 
the first report of a decreased production of the Th2 cytokines IL-5 and IL-13 after tetracycline exposure. Due to 
the properties of those two cytokines, this observation could explain at least in part the decreased airway 
responsiveness, reduced eosinophilic inflammation and airway remodeling prevention [5, 6, 34]. To date, the 
precise mechanism of action of the inhaled steroid fluticasone leading to control of inflammation is also not 
really well understood. However, our result suggests different mechanism of action between fluticasone and 
Doxycycline regarding the differences found in their respective effects on IL-10 production. The finding of an 
increased IL-10 production is of great interest since a relative IL-10 deficiency could favour asthma. Indeed, the 
number of IL-10-producing T cells has been reported to be lower in severe asthmatics when compared to milder 
patients [35] and IL-10 production is increased in the BAL cells of mice exposed to an immunotherapy protocol 
[36]. IL-10 has also been shown to decrease eosinophil survival and cytokine secretion [37] and could even 
mediate a part of the anti-inflammatory effects of steroid [38]. Finally, IL-10 interacts with the MMP 
metabolism since it inhibits MMP-2 and -14 transcription in some cancer cell lines [39,40]. Taken together, these 
data suggest that doxycycline-induced IL-10 production could inhibit the allergen-induced airway inflammation 
and airway remodeling (collagen deposition and membrane thickening) both indirectly by diminishing the venue 
of inflammatory cells and directly by inhibiting MMP transcription. Altogether, our data about cytokine 
measurements suggest an inhibition of Th2 inflammation and a possible stimulation of T regulatory lymphocytes 
(Treg) by doxycycline inhalation [32]. 
Doxycycline decreases the inducible nitric oxide synthase (NOS) activity as demonstrated in vitro [41] and in an 
animal model of LPS exposure [42]. As a correlation has been found between nitric oxide production and the 
extent of airway remodeling in humans [43], another possible explanation of our findings could reside in an 
inhibition of nitric oxide synthesis by tetracyclines. 
Nevertheless, direct MMP inhibition by doxycycline is thought to be the main cause of many pharmacological 
effects of tetracyclines. Indeed, doxycycline has been proposed as a therapy to reduce MMP activation and 
expression (particularly MMP-2 and -9) in abdominal aortic aneurysms [44] and has been reported to decrease 
pathological remodeling after myocardial infarction in rat [45]. Doxycycline has the ability to inhibit MMPs 
belonging to the gelatinase subfamily [17,46] but this compound also inhibit other MMPs as MMP-3 and MMP-
7 [47]. Moreover, doxycycline has been described to have putative inhibitory effects on members of collagenase 
subfamily of MMPs. Indeed, doxycycline is quite effective on MMP-8 and MMP-13 inhibition and, in a lesser 
extent, on MMP-1 [19,48]. In the present study, we can not rule out, however, that an inhibition of non-
gelatinase members of the MMP family could cause some side effects. In the present work, mice exposed to 
doxycycline for up to 96 days did not display any sign of exaggerated inflammation or any visible toxicity. In the 
present study we demonstrate that, after doxycycline exposure, global MMP activity in lung tissue is decreased 
and that the proportion of activated MMP-9 is lower than measured in vehicle-exposed mice. This strongly 
suggests that, in our study, a significant part of the pharmacological effect obtained with doxycycline is linked to 
a direct MMP inhibition as the central role of MMP-9 in the allergen-induced inflammation has been described 
elsewhere using the same protocol of allergen immunisation and exposure. 
In conclusion, the administration of doxycycline by aerosols in a complex with HP-gamma-CD prevents the 
allergen-induced airway inflammation and remodeling by modulation of both MMPs and interleukins. 
Doxycycline should be considered for other studies designed to confirm its disease modifying agent role in 
asthma. Our results suggest that inhaled doxycycline should be investigated as a potential new therapy for 
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